Posted on 28/09/2009 in Pharmaceutical Company Product News Galderma and Ipsen have announced that a product of their partnership - the glabellar line treatment Azzalure (botulinum toxin type A) - has received approval from authorities.
Following successful trials, the aesthetic local muscle relaxant Azzalure has been authorised by the Spanish Medicines and Healthcare products Agency (AEMPS) for use in adult men and women aged 65 years and under.
It is designed specifically for the temporary improvement in the appearance of moderate to severe glabellar lines seen in the frown area between the eyebrows.
Francisco Javier Gonzalez, Galderma's general manager for Spain and Portugal, said: "Patients can look forward to benefiting from Galderma's years of experience in dermatology and our commitment to providing the highest standards of medical education and training to healthcare professionals."
Galderma and Ipsen have been working together on the development of skin products since 2007 and its Azzalure contract encompasses the European Union, areas of the Middle East and Eastern Europe.
Other news stories from 28/09/2009
Read more in the Zenopa News Archive
How this news is generated
|
